beta

ACHN

Achillion Pharmaceuticals Inc.

Achn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-07-2018 08-08-2018 05-02-2018 02-22-2018 11-01-2017 08-08-2017 after market close 05-04-2017
Actual EPS -0.12 -0.12 -0.15 -0.17 -0.14 -0.16 -0.15
Consensus EPS -0.14 -0.13 -0.14 -0.15 -0.18 -0.16 -0.08
Estimated EPS -0.14 -0.13 -0.14 -0.15 -0.18 -0.16 -0.08
Number of Estimates 2 2 3 3 3 3 4
EPS Surprise $0.02 $0.01 -$0.01 -$0.02 $0.04 -$0.07

Stats

Summary

Achillion Pharmaceuticals Inc is a biotechnology company. It is engaged in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders.

Market Cap: 396 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.achillion.com

Shares Outstanding: 138 Million

Float: 138 Million

Dividend: 0.0 (0.0%)

Beta: 1.356592

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 6.08 Million

Ethical Flags

Animal testing

Longest drawdown: 988 trading days

From: 2015-01-23 To: 2018-12-14

Lowest Point:

Time To Connect The Dots (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-12-16 08:04:21:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look … read more...

Stocks To Watch: Time To Connect The Dots

via: SeekingAlpha at 2018-12-15 09:12:29:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There are two monster meetings on the agenda next week that could shake things up f… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-12-14 09:54:28:000

Noteworthy events during the week of December 16 - 22 for healthcare investors. More news on: Innovate Biopharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., ADMA Biologics Inc, Healthcare stocks news, , Read more … read more...

Achillion Pharmaceuticals: Overlooked Value Play Or Potential Trap?

via: SeekingAlpha at 2018-11-28 13:21:27:000

2018 Third Quarter Recap and Update Achillion Pharmaceuticals (NASDAQ: ACHN)) reported Q3 earnings November 7 th , 2018, with a mixed reaction from the market in the following week. Initially, the stock popped up to approximately $3/share but shortly after dropped to a low of around $2.60/… read more...

Achillion Pharmaceuticals: Overlooked Value Play Or Potential Trap?

via: SeekingAlpha at 2018-11-28 13:21:27:000

2018 Third Quarter Recap and Update Achillion Pharmaceuticals (NASDAQ: ACHN)) reported Q3 earnings November 7 th , 2018, with a mixed reaction from the market in the following week. Initially, the stock popped up to approximately $3/share but shortly after dropped to a low of around $2.60/… read more...

Achillion Pharmaceuticals: Overlooked Value Play Or Potential Trap?

via: SeekingAlpha at 2018-11-28 13:21:27:000

2018 Third Quarter Recap and Update Achillion Pharmaceuticals (NASDAQ: ACHN)) reported Q3 earnings November 7 th , 2018, with a mixed reaction from the market in the following week. Initially, the stock popped up to approximately $3/share but shortly after dropped to a low of around $2.60/… read more...

Achillion Pharmaceuticals beats by $0.02

via: SeekingAlpha at 2018-11-07 06:03:40:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12 beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Achillion Pharmaceuticals beats by $0.02

via: SeekingAlpha at 2018-11-07 06:03:40:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12 beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Achillion Pharmaceuticals beats by $0.02

via: SeekingAlpha at 2018-11-07 06:03:40:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12 beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs

via: SeekingAlpha at 2018-09-26 08:14:53:000

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...

Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs

via: SeekingAlpha at 2018-09-26 08:14:53:000

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...

Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs

via: SeekingAlpha at 2018-09-26 08:14:53:000

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...

Achillion appoints Dr. Steven Zelenkofske as Chief Medical Officer

via: SeekingAlpha at 2018-08-21 06:18:52:000

Achillion Pharmaceuticals (NASDAQ: ACHN ) appoints Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Achillion appoints Dr. Steven Zelenkofske as Chief Medical Officer

via: SeekingAlpha at 2018-08-21 06:18:52:000

Achillion Pharmaceuticals (NASDAQ: ACHN ) appoints Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Achillion appoints Dr. Steven Zelenkofske as Chief Medical Officer

via: SeekingAlpha at 2018-08-21 06:18:52:000

Achillion Pharmaceuticals (NASDAQ: ACHN ) appoints Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Achillion Pharmaceuticals beats by $0.01

via: SeekingAlpha at 2018-08-08 16:51:47:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q2 EPS of -$0.12 beats by $0.01 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Achillion Pharmaceuticals beats by $0.01

via: SeekingAlpha at 2018-08-08 16:51:47:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q2 EPS of -$0.12 beats by $0.01 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Achillion Pharmaceuticals beats by $0.01

via: SeekingAlpha at 2018-08-08 16:51:47:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q2 EPS of -$0.12 beats by $0.01 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-07-15 02:25:07:000

Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...

Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-07-15 02:25:07:000

Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...

Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-07-15 02:25:07:000

Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...

Midday Gainers / Losers (07/13/2018)

via: SeekingAlpha at 2018-07-13 12:37:51:000

Gainers: BIOC +73% . PIXY +55% . SNES +24% . GLMD +20% . ADXS +17% . CFMS +14% . IFRX +13% . ACHN +11% . RUBI +11% . ZGNX +11% . More news on: Biocept, Inc., ShiftPixy, SenesTech, Stocks on the move, , Read more … read more...

Midday Gainers / Losers (07/13/2018)

via: SeekingAlpha at 2018-07-13 12:37:51:000

Gainers: BIOC +73% . PIXY +55% . SNES +24% . GLMD +20% . ADXS +17% . CFMS +14% . IFRX +13% . ACHN +11% . RUBI +11% . ZGNX +11% . More news on: Biocept, Inc., ShiftPixy, SenesTech, Stocks on the move, , Read more … read more...

Achillion Is A Worthwhile Biotech Speculation

via: SeekingAlpha at 2018-07-12 12:51:34:000

Investment Thesis Achillion Pharmaceuticals ( ACHN ) is a high conviction speculative pick for us given the strong balance sheet, Orphan drug pipeline, and focus on core compounds which have shown potential for multiple applications. With the compelling research pipeline over the next 2-3 … read more...

Your Daily Pharma Scoop: Kamada Phase 3 Approved, Vivus Positive, IsoRay Down

via: SeekingAlpha at 2018-07-12 06:28:07:000

Stocks in News: KMDA, VVUS, CHMP on board with design of late-stage study of Kamada's inhaled AAT for AATD; shares up 4% premarket Discussion : Kamada Ltd. ( KMDA ) announced that EMA advisory group CHMP approved the general design of the Phase 3 clinical trial of inhaled alpha-1 anti… read more...

Achillion launches early-stage study of next-gen complement factor D inhibitor

via: SeekingAlpha at 2018-07-10 07:45:00:000

Dosing is underway in a 28-subject Phase 1 clinical trial assessing Achillion Pharmaceuticals' (NASDAQ: ACHN ) next-generation complement factor D inhibitor, ACH-5548, in healthy volunteers. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Achillion launches early-stage study of next-gen complement factor D inhibitor

via: SeekingAlpha at 2018-07-10 07:45:00:000

Dosing is underway in a 28-subject Phase 1 clinical trial assessing Achillion Pharmaceuticals' (NASDAQ: ACHN ) next-generation complement factor D inhibitor, ACH-5548, in healthy volunteers. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt

via: SeekingAlpha at 2018-07-09 12:45:57:000

Welcome to Achillion ( ACHN ) - I've been following the company for a bit, but only after the JNJ Hep C disaster, so I won't be painting much of a picture for that asset, nor times before it. Rather I want to focus on lead asset 4471 and their second-generation drugs. And the ridiculous amount… read more...

Institutional Top Ideas: EcoR1 Capital

via: SeekingAlpha at 2018-06-12 02:08:54:000

In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...

Institutional Top Ideas: EcoR1 Capital

via: SeekingAlpha at 2018-06-12 02:08:54:000

In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...

Institutional Top Ideas: EcoR1 Capital

via: SeekingAlpha at 2018-06-12 02:08:54:000

In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...

Institutional Top Ideas: EcoR1 Capital

via: SeekingAlpha at 2018-06-12 02:08:54:000

In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...

Institutional Top Ideas: EcoR1 Capital

via: SeekingAlpha at 2018-06-12 02:08:54:000

In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-21 08:19:20:000

AMAG Pharmaceuticals (NASDAQ: AMAG ) initiated with Market Perform rating and $26 (5% upside) price target at Leerink. More news on: AMAG Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Sabra Healthcare REIT, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-21 08:19:20:000

AMAG Pharmaceuticals (NASDAQ: AMAG ) initiated with Market Perform rating and $26 (5% upside) price target at Leerink. More news on: AMAG Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Sabra Healthcare REIT, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-18 16:37:17:000

Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-18 16:37:17:000

Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more … read more...

Institutional Top Ideas Series: Opaleye Management

via: SeekingAlpha at 2018-05-17 01:52:55:000

In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund weve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Opaleye Management

via: SeekingAlpha at 2018-05-17 01:52:55:000

In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund weve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Achillion Pharmaceuticals misses by $0.01

via: SeekingAlpha at 2018-05-02 09:07:27:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 EPS of -$0.15 misses by $0.01 . Cash, cash equivalents, marketable securities and interest receivable of $308.4M Shares +0.53% PM. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare … read more...

Achillion Pharmaceuticals misses by $0.01

via: SeekingAlpha at 2018-05-02 09:07:27:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 EPS of -$0.15 misses by $0.01 . Cash, cash equivalents, marketable securities and interest receivable of $308.4M Shares +0.53% PM. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare … read more...

Achillion Pharmaceuticals misses by $0.01

via: SeekingAlpha at 2018-05-02 09:07:27:000

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 EPS of -$0.15 misses by $0.01 . Cash, cash equivalents, marketable securities and interest receivable of $308.4M Shares +0.53% PM. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare … read more...

Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

via: SeekingAlpha at 2018-04-09 13:39:22:000

I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...

Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

via: SeekingAlpha at 2018-04-09 13:39:22:000

I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...

Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

via: SeekingAlpha at 2018-04-09 13:39:22:000

I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...

Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-03-31 09:55:20:000

Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select… read more...

Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-03-31 09:55:20:000

Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select… read more...

Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-03-31 09:55:20:000

Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select… read more...

Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow

via: SeekingAlpha at 2018-03-16 15:11:37:000

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow

via: SeekingAlpha at 2018-03-16 15:11:37:000

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow

via: SeekingAlpha at 2018-03-16 15:11:37:000

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket

via: SeekingAlpha at 2018-03-15 07:30:55:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...

Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket

via: SeekingAlpha at 2018-03-15 07:30:55:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...

Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket

via: SeekingAlpha at 2018-03-15 07:30:55:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...

3 Things In Biotech You Should Learn Today: February 27, 2018

via: SeekingAlpha at 2018-02-28 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Arca Bio crushed on poor heart trial results Company: Arca Bio ( ABIO ) Therapy: Buci… read more...

3 Things In Biotech You Should Learn Today: February 27, 2018

via: SeekingAlpha at 2018-02-28 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Arca Bio crushed on poor heart trial results Company: Arca Bio ( ABIO ) Therapy: Buci… read more...

3 Things In Biotech You Should Learn Today: February 27, 2018

via: SeekingAlpha at 2018-02-28 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Arca Bio crushed on poor heart trial results Company: Arca Bio ( ABIO ) Therapy: Buci… read more...

Your Daily Pharma Scoop: Progenics Update, La Jolla Data, ARCA Biopharma Setback

via: SeekingAlpha at 2018-02-27 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics Pharmaceuticals ( PGNX ), which last week presented at the RBC Capital Markets Global Healthcare Conference. As we have noted before, Progenics has an important upcoming catalyst, which could provide a si… read more...

Your Daily Pharma Scoop: Progenics Update, La Jolla Data, ARCA Biopharma Setback

via: SeekingAlpha at 2018-02-27 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics Pharmaceuticals ( PGNX ), which last week presented at the RBC Capital Markets Global Healthcare Conference. As we have noted before, Progenics has an important upcoming catalyst, which could provide a si… read more...

Midday Gainers / Losers (2/26/2018)

via: SeekingAlpha at 2018-02-26 12:49:58:000

Gainers: NXTD +30% . TAHO +20% . RCM +20% . ZSAN +18% . TTPH +18% . APLS +16% . XTNT +15% . DTRM +14% . CGEN +14% . ACHN +14% . More news on: NXT-ID Inc., Tahoe Resources Inc., R1 RCM Inc., Stocks on the move, , Read more … read more...

Achillion's ACH-4471 receives positive opinion for ODD in Europe for the treatment of C3 glomerulopathy

via: SeekingAlpha at 2018-02-26 06:50:55:000

Achillion Pharmaceuticals (NASDAQ: ACHN ) announces that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug status for ACH-4471 for the treatment of C3 glomerulopathy (C3G). More news on: Achil… read more...

Achillion Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-23 13:14:01:000

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-08 08:39:57:000

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-08 08:39:57:000

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-08 08:39:57:000

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-08 08:39:57:000

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...

Stocks To Watch: Guidance Updates All Around

via: SeekingAlpha at 2018-01-13 10:15:28:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...

Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value

via: SeekingAlpha at 2018-01-09 11:31:28:000

Background of the Company Achillion ( ACHN ) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. The complement system is a part of the human innate immune system and is believed to comprise three pathways - the alt… read more...

How I Beat The Market In 2017

via: SeekingAlpha at 2018-01-09 10:19:44:000

Benjamin Graham preached that, if one is to take an active (rather than passive) approach to investing, one must treat it as a business. As someone who has started and helped to run multiple businesses, I understand the commitment this entails. It means spending your time researching as if… read more...

Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering

via: SeekingAlpha at 2017-12-19 08:04:09:000

Content Analysis of coverage: RARE Stocks in the news: REGN, MDGL Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Subscriber Questions & Answers (for TPT Subscribers only) Catalyst Rundown (for… read more...

3 Things In Biotech You Should Learn Today: December 19, 2017

via: SeekingAlpha at 2017-12-19 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Achillion reports phase 1 data in kidney disease Company: Achillion Pharmaceuticals ( ACH… read more...

Achillion's ACH-4471 granted ODD for the treatment of C3G; initiated Phase 1 extended-release bioavailability study

via: SeekingAlpha at 2017-12-18 07:43:29:000

Achillion Pharmaceuticals (NASDAQ: ACHN ) announces that the FDA has granted Orphan Drug status for ACH-4471 for the treatment of patients with C3 Glomerulopathy (C3G). More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Achillion CMO to leave this month

via: SeekingAlpha at 2017-12-15 11:27:03:000

Achillion Pharmaceuticals ( ACHN -0.5% ) EVP, Chief Medical Officer David Apelian, M.D., Ph.D. will resign effective December 28 to pursue a position elsewhere. A search for a successor is underway. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more ….. read more...

Akari's Coversin successful in mid-stage PNH study

via: SeekingAlpha at 2017-12-08 16:39:08:000

A Phase 2 clinical trial, COBALT , assessing Akari Therapeutics' (NASDAQ: AKTX ) lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a statistically significant reduction in LDH (lactate dehydrogenase) to within 1.8x the upper lim… read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-11-24 15:04:46:000

Top gainers: CYTK +3.9% . PAA +3.7% . SOGO +1.7% . REDU +1.2% . ACHN +0.9% . More news on: Cytokinetics, Incorporated, Plains All American Pipeline, L.P., Sogou, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2017-11-16 09:26:39:000

CADC +198% . More news on: China Advanced Construction Materials Group, Inc., SemiLEDs Corporation, Time Inc., Stocks on the move, Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX